先为达生物携手辉瑞中国 加速偏向型GLP-1商业化进程

Core Insights - Hangzhou Xianweida Biotechnology Co., Ltd. and Pfizer China have entered into a strategic commercialization agreement for Ecnoglutide injection, a next-generation GLP-1 receptor agonist, granting Pfizer exclusive commercialization rights in mainland China [1][2] - Xianweida will act as the marketing authorization holder (MAH) for the licensed product, responsible for its research, registration, production, and supply, and is set to receive up to $495 million in total payments from Pfizer, including upfront, registration, and sales milestone payments [1][2] Company Overview - Ecnoglutide is a self-developed next-generation cAMP-biased GLP-1 receptor agonist aimed at providing precise treatment options for type 2 diabetes and long-term weight management [2] - Clinical studies have shown that Ecnoglutide injection resulted in an average weight reduction of 15.1% in the Chinese population, with 92.8% of patients achieving clinically significant weight loss and over 80% meeting blood sugar targets (HbA1c < 7.0%) [2] Strategic Importance - The partnership marks Pfizer's first step in its global metabolic strategy in China, with both companies aiming to leverage their strengths to enhance treatment options for obesity and metabolic diseases [1][2] - The collaboration aligns with China's health initiatives, as the adult obesity rate is currently 14.1%, closely linked to metabolic diseases, and "healthy weight management" has been officially included in the Healthy China Action [2]